Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.LIZ HUNT
Medical Correspondent
Thousands of American Aids patients are joining a lottery to decide who will get access to free experimental drugs before they are proven safe and effective in clinical trials.
The United States Food and Drug Administration (FDA) has approved a scheme which gives the drugs to some patients in the final stages of Aids for whom all other therapies have failed. British Aids activists have condemned the lottery as "inhuman" and say it will not be allowed here.
Under the scheme, more than 1,000 eligible Aids patients will be selected at random by an independent auditor, and the remainder placed on a waiting list for the drugs, known as protease inhibitors, an FDA spokesman said yesterday.
In the absence of any viable vaccine against HIV, the protease inhibitors which work by blocking a vital enzyme the virus needs to replicate, are viewed as the "last great hope", according to a spokesman for ACT-UP, an Aids activist group in New York.
The decision by manufacturers, Merck & Co. and Hoffman-La Roche, has been dismissed as a cynical marketing ploy designed to create publicity and demand for the drugs.
Negotiations are underway with Hoffman-La Roche to introduce a similar "expanded access" programme for its drug, Invirase, in Europe. Merck is also seeking 750 patients from outside the US to take its drug, Crixivan.
Robin Gorna of the Terence Higgins Trust which is involved in negotiations, said yesterday. "[Expanded access] is a good option for people in dire need who are not responding to AZT and whose CD4 [white blood cells] are falling. But it really is inhuman to give out the drugs in what is a lottery. British patients who get the drugs will have to meet strict criteria."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments